Education
About Us
Working with TipRanks
Follow Us
Personalis (PSNL)
NASDAQ:PSNL
PSNL Stock Chart & Stats
$7.83
-$0.70(-11.71%)
At close: 4:00 PM EST
$7.83
-$0.70(-11.71%)
Day’s Range― - ―
52-Week Range$2.83 - $11.50
Previous CloseN/A
Volume738.16K
Average Volume (3M)1.18M
Market Cap
$715.32M
Enterprise Value$687.24M
Total Cash (Recent Filing)$150.51M
Total Debt (Recent Filing)$41.87M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Feb 19, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding88,804,350
10 Day Avg. Volume1,143,472
30 Day Avg. Volume1,183,502
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)4.05
P/FCF Ratio-7.33
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue9.95
Enterprise Value/Gross Profit37.30
Enterprise Value/Ebitda-10.79
Forecast
1Y Price Target
$11.33Price Target Upside44.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And FinancingA large cash raise via an ATM facility materially de-risked the balance sheet and provides funding to support an expanded commercial launch and operational scale-up.
Commercial TractionAccelerating clinical test volumes and rising clinical test revenue point to growing market demand and commercial traction for the company's testing services.
Reimbursement CoverageMedicare coverage for the NeXT Personal test in breast cancer enables reimbursement for post-treatment monitoring and supports broader payer acceptance that can boost clinical testing revenue.
Bears Say
Operational And Legal RisksConcentration of customers, legal and intellectual property exposure, intense competition, and financial risks increase the chance of operational setbacks that could harm results.
Reporting UncertaintyAnalyst intent to wait for full reported results before updating models reflects uncertainty about reported performance and could prolong stock volatility.
Revenue Forecasts And CompetitionAnalyst cuts to revenue forecasts tied to a pre-announcement shortfall and competitive pressure from a rival indicate potential near-term revenue downside if market share shifts.
Personalis News
PSNL FAQ
What was Personalis’s price range in the past 12 months?
Personalis lowest stock price was $2.83 and its highest was $11.50 in the past 12 months.
What is Personalis’s market cap?
Personalis’s market cap is $715.32M.
When is Personalis’s upcoming earnings report date?
Personalis’s upcoming earnings report date is Feb 19, 2026 which is in 8 days.
How were Personalis’s earnings last quarter?
Personalis released its earnings results on Nov 04, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.267 by $0.027.
Is Personalis overvalued?
According to Wall Street analysts Personalis’s price is currently Undervalued.
Does Personalis pay dividends?
Personalis does not currently pay dividends.
What is Personalis’s EPS estimate?
Personalis’s EPS estimate is -0.29.
How many shares outstanding does Personalis have?
Personalis has 88,804,350 shares outstanding.
What happened to Personalis’s price movement after its last earnings report?
Personalis reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.267. Following the earnings report the stock price went down -12.257%.
Which hedge fund is a major shareholder of Personalis?
Currently, no hedge funds are holding shares in PSNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Personalis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.33 (44.70% Upside)
$11.33 (44.70% Upside)
Blogger Sentiment
Bullish
PSNL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.14%
12-Months-Change
Fundamentals
Return on Equity
-43.69%
Trailing 12-Months
Asset Growth
1.23%
Trailing 12-Months
Company Description
Personalis
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
PSNL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong clinical adoption and strategic partnerships, but also revealed significant revenue and margin challenges. While the company is confident in its clinical and reimbursement advancements, financial performance faced headwinds due to biopharma volatility and revenue declines.View all PSNL earnings summariesPSNL Stock 12 Month Forecast
Average Price Target
$11.33
▲(44.70% Upside)
Technical Analysis
Ownership Overview
0.68% Insiders
8.66% Mutual Funds
0.09% Other Institutional Investors
74.20% Public Companies and
Individual Investors